342 related articles for article (PubMed ID: 36552755)
1. Acute Kidney Injury in Cancer Immunotherapy Recipients.
Joseph A; Lafarge A; Azoulay E; Zafrani L
Cells; 2022 Dec; 11(24):. PubMed ID: 36552755
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors and acute kidney injury.
Zhou P; Gao Y; Kong Z; Wang J; Si S; Han W; Li J; Lv Z; Wang R
Front Immunol; 2024; 15():1353339. PubMed ID: 38464524
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know.
Jhaveri KD; Rosner MH
Clin J Am Soc Nephrol; 2018 May; 13(5):796-798. PubMed ID: 29523675
[No Abstract] [Full Text] [Related]
5. The nephrotoxicity of new immunotherapies.
Sury K; Perazella MA
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):513-521. PubMed ID: 31035801
[No Abstract] [Full Text] [Related]
6. Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.
Zhou H; Yang M; Cui L; Jiang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107072. PubMed ID: 33059198
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy-Related Acute Kidney Injury.
Manohar S; Jhaveri KD; Perazella MA
Adv Chronic Kidney Dis; 2021 Sep; 28(5):429-437.e1. PubMed ID: 35190109
[TBL] [Abstract][Full Text] [Related]
8. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.
Kroschinsky F; Stölzel F; von Bonin S; Beutel G; Kochanek M; Kiehl M; Schellongowski P;
Crit Care; 2017 Apr; 21(1):89. PubMed ID: 28407743
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
11. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
12. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.
Gupta S; Seethapathy H; Strohbehn IA; Frigault MJ; O'Donnell EK; Jacobson CA; Motwani SS; Parikh SM; Curhan GC; Reynolds KL; Leaf DE; Sise ME
Am J Kidney Dis; 2020 Jul; 76(1):63-71. PubMed ID: 31973908
[TBL] [Abstract][Full Text] [Related]
13. T cell-engaging therapies - BiTEs and beyond.
Goebeler ME; Bargou RC
Nat Rev Clin Oncol; 2020 Jul; 17(7):418-434. PubMed ID: 32242094
[TBL] [Abstract][Full Text] [Related]
14. Cancer immune therapy for lymphoid malignancies: recent advances.
Klausen U; Jørgensen NGD; Grauslund JH; Holmström MO; Andersen MH
Semin Immunopathol; 2019 Jan; 41(1):111-124. PubMed ID: 30006739
[TBL] [Abstract][Full Text] [Related]
15. From antibodies to living drugs: Quo vadis cancer immunotherapy?
Szöőr Á; Szöllősi J; Vereb G
Biol Futur; 2021 Mar; 72(1):85-99. PubMed ID: 34554498
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514
[TBL] [Abstract][Full Text] [Related]
17. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.
Zhang E; Xu H
J Hematol Oncol; 2017 Jan; 10(1):1. PubMed ID: 28049484
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
Fishman JA; Hogan JI; Maus MV
Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.
Rashidijahanabad Z; Huang X
Semin Immunol; 2020 Feb; 47():101390. PubMed ID: 31982247
[TBL] [Abstract][Full Text] [Related]
20. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer.
Sivaganesh V; Promi N; Maher S; Peethambaran B
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
